文献速递艾滋病与性传播感染病毒性肝炎

HIV感染者中丙型肝炎感染与非肝脏相关疾病和死亡风险

Hepatitis C Infection and the Risk of Non-Liver-Related Morbidity and Mortality in HIV-Infected Persons in the Swiss HIV Cohort Study.
PubMed 文献 · Clin Infect Dis · 2017-01-01

瑞士HIV队列研究纳入2503例HCV血清阳性者和2503例匹配的HCV血清阴性者,随访平均8.2年。HCV血清阳性者肝脏事件、肝脏相关死亡、肾脏事件和骨质疏松/骨折风险增加,但肾脏和骨折风险似乎不依赖持续HCV RNA。成功HCV治疗与较低的肝病、肝脏相关死亡和糖尿病发生率相关。

要点

  • HCV血清阳性HIV感染者肝脏事件(IRR 6.29)、肝脏相关死亡(IRR 8.24)、肾脏事件(IRR 2.43)和骨质疏松/骨折(IRR 1.43)风险增加。
  • 治疗未获SVR者较获SVR者肝脏事件(IRR 6.79)、肝脏相关死亡(IRR 3.29)和糖尿病(IRR 4.62)风险更高。
  • HCV暴露增加的肾脏和骨质疏松/骨折风险似乎不依赖持续HCV RNA。

核心结论

  • HCV暴露与肾脏疾病和骨质疏松/骨折风险增加相关,但该风险似乎不依赖持续HCV RNA。
  • 成功HCV治疗与较低的肝病、肝脏相关死亡和糖尿病发生率相关,其他研究疾病受影响较小。

研究设计与样本

  • 瑞士HIV队列研究,1994年8月至2014年12月,纳入2503例HCV血清阳性HIV感染者和2503例发病率密度匹配的HCV血清阴性对照。
  • 比较HCV血清阳性与血清阴性者,以及HCV病毒血症者与成功治疗的非病毒血症者,采用泊松回归评估差异。

主要发现

  • HCV血清阳性者与血清阴性者分别发生肝脏事件107和18例、肾脏事件41和14例、骨质疏松/骨折230和121例、糖尿病82和94例、心血管事件114和129例、非AIDS恶性肿瘤119和147例、CDC HIV B/C类事件162和126例、肝脏相关死亡106和10例、非肝脏相关死亡227和218例。
  • HCV血清阳性者较血清阴性者肝脏事件IRR 6.29(95%CI 3.52–11.22)、肝脏相关死亡IRR 8.24(95%CI 3.61–18.83)、肾脏事件IRR 2.43(95%CI 1.11–5.33)、骨质疏松/骨折IRR 1.43(95%CI 1.03–2.01)。
  • HCV血清阳性者中,治疗未获SVR者较获SVR者肝脏事件IRR 6.79(95%CI 2.33–19.81)、肝脏相关死亡IRR 3.29(95%CI 1.35–8.05)、糖尿病IRR 4.62(95%CI 1.53–13.96)。
  • 未治疗HCV RNA阳性者与获SVR者之间差异相似但无统计学显著性。

临床怎么用

  • HIV合并HCV感染者应关注肾脏疾病和骨质疏松/骨折风险,即使HCV RNA已清除。
  • 成功HCV治疗(获SVR)可能降低肝病、肝脏相关死亡和糖尿病风险,应积极治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hepatitis C virus (HCV) infection has been associated with increased non-liver-related morbidity and mortality. However, studies have yielded inconsistent results. METHODS: The incidence of clinical events in human immunodeficiency virus (HIV)–infected HCV-seropositive and incidence density–matched HCV-seronegative participants of the Swiss HIV Cohort Study from August 1994 to December 2014 was studied. We compared (1) HCV-seropositive with HCV-seronegative participants and (2) HCV-viremic with successfully treated nonviremic patients. Poisson regression was used to assess differences between these groups. RESULTS: We included 2503 HCV-seropositive participants (540 with spontaneous HCV clearance, 1294 untreated HCV RNA positive, 345 treated with sustained virologic response [SVR], 43 during treatment, and 281 treated without SVR), and 2503 HCV-seronegative controls. After a mean follow-up of 8.2 years, we observed (HCV seropositive and HCV seronegative, respectively) 107 and 18 liver events, 41 and 14 kidney events, 230 and 121 osteoporosis/fractures, 82 and 94 diabetes mellitus, 114 and 129 cardiovascular events, 119 and 147 non-AIDS malignancies, 162 and 126 Centers for Disease Control and Prevention HIV category B/C events, 106 and 10 liver-related deaths, and 227 and 218 non-liver-related deaths. Compared with HCV-negative controls, HCV-seropositive participants had an increased risk of liver events (incidence rate ratio [IRR], 6.29 [95% confidence interval {CI}, 3.52–11.22]), liver-related death (IRR, 8.24 [95% CI, 3.61–18.83]), kidney events (IRR, 2.43 [95% CI, 1.11–5.33]), and osteoporosis/fracture (IRR, 1.43 [95% CI, 1.03–2.01]). Among HCV-seropositive individuals, treated participants without SVR vs those with SVR had a higher risk of liver events (IRR, 6.79 [95% CI, 2.33–19.81]), liver-related death (IRR, 3.29 [95% CI, 1.35–8.05]), and diabetes mellitus (IRR, 4.62 [95% CI, 1.53–13.96]). Similar but not statistically significant differences were found between untreated HCV RNA–positive patients and those with SVR. CONCLUSIONS: While HCV exposure was associated with an increased risk of kidney disease and osteoporosis/fracture, this risk did not seem to be dependent of persistent HCV RNA. Successful HCV treatment was associated with a lower incidence of liver disease, liver-related death, and diabetes mellitus, whereas the other conditions studied were less affected.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Kovari H, Rauch A, Kouyos R, et al. Hepatitis C Infection and the Risk of Non-Liver-Related Morbidity and Mortality in HIV-Infected Persons in the Swiss HIV Cohort Study. Clin Infect Dis. 2017. PMID: 28172403. doi:10.1093/cid/ciw809

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。